date:Aug 01, 2018
ietary supplements.
However, in an email for this article, Al-Mondhiry cautioned, [T]he purpose of the IND [investigational new drug] preclusion is to protect the drug industrys investment, so authorizing use as a dietary ingredient after drug approval seems counter to that purpose and would likely draw the ire of the drug industry.
Regulatory attorney Steven Shapiro said GW Pharmaceuticals has likely invested hundreds of millions of dollars to develop its drug, if not more.
The way the statu